YAP1 and non-small cell lung carcinoma: To summarize all that we have gathered, OTUD1 reversed NSCLC cell resistance to erlotinib via inactivation of the SOX9/SPP1 axis by inhibiting the nuclear translocation of YAP1, underlying a novel mechanism of the anti-oncogenic OTUD1 in NSCLC (Fig. 6).